Dabigatran should be avoided when CrCl is <30 mL/min; for CrCl 15-30 mL/min there is a labeling dose based on PK data. Which drug is this?

Study for the AGS Beers Criteria Test. Prepare with flashcards and multiple choice questions, each with hints and explanations. Get ready for your exam with comprehensive resources!

Multiple Choice

Dabigatran should be avoided when CrCl is <30 mL/min; for CrCl 15-30 mL/min there is a labeling dose based on PK data. Which drug is this?

Explanation:
Dabigatran is the drug that matches this dosing pattern because it is predominantly cleared by the kidneys, so renal function has a large impact on its blood levels and bleeding risk. When CrCl falls below 30 mL/min, the drug is generally avoided to minimize accumulation. If CrCl is in the 15–30 mL/min range, the labeling provides a reduced, PK-guided dose (typically a lower dose like 75 mg twice daily) to balance efficacy and safety based on pharmacokinetic data. Other anticoagulants in this group have different renal adjustment rules and do not rely on this exact PK-based dosing approach for the 15–30 mL/min range, which is why this pattern points to dabigatran.

Dabigatran is the drug that matches this dosing pattern because it is predominantly cleared by the kidneys, so renal function has a large impact on its blood levels and bleeding risk. When CrCl falls below 30 mL/min, the drug is generally avoided to minimize accumulation. If CrCl is in the 15–30 mL/min range, the labeling provides a reduced, PK-guided dose (typically a lower dose like 75 mg twice daily) to balance efficacy and safety based on pharmacokinetic data. Other anticoagulants in this group have different renal adjustment rules and do not rely on this exact PK-based dosing approach for the 15–30 mL/min range, which is why this pattern points to dabigatran.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy